BTLA: a new inhibitory receptor with a B7-like ligand.
The B and T lymphocyte attenuator, BTLA, is a recently discovered Ig superfamily member. BTLA engagement results in downregulation of T-cell activation, and mice deficient in BTLA show increased incidence and severity of autoimmune disorders. A novel B7 family member, B7x (B7S1, B7-H4), has been proposed as the ligand for BTLA. A B7x-Ig fusion protein inhibits T-cell activation and interleukin-2 (IL-2) production. Thus, cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1) and BTLA comprise an expanding set of inhibitory receptors expressed on lymphocytes.
Carreno
Beatriz M
BM
Inflammation, Wyeth Research, 200 Cambridge Park Drive, Cambridge, MA 02140, USA. bcarreno@wyeth.com
Collins
Mary
M
D000818:Animals; D001402:B-Lymphocytes / Q000502:physiology*; D018122:B7-1 Antigen / Q000502:physiology*; D005803:Genes, Immunoglobulin; D006801:Humans; D008024:Ligands; D008213:Lymphocyte Activation; D011948:Receptors, Antigen, T-Cell / Q000502:physiology*; D011971:Receptors, Immunologic / Q000502:physiology*; D015398:Signal Transduction / Q000502:physiology*; D013601:T-Lymphocytes / Q000502:physiology*; D060907:V-Set Domain-Containing T-Cell Activation Inhibitor 1
D018122:B7-1 Antigen; D008024:Ligands; D011948:Receptors, Antigen, T-Cell; D011971:Receptors, Immunologic; D060907:V-Set Domain-Containing T-Cell Activation Inhibitor 1; C475826:VTCN1 protein, human; C475824:Vtcn1 protein, mouse